Because DLB and AD share many clinical features, which implies common underlying pathophysiology (Samuel et al., 1997), the pharmacological therapy strategies for AD, such as cholinesterase inhibitors and N-methyl-D-aspartate glutamate receptor antagonists (e.g., memantine), are used to alleviate DLB symptoms. The gene discussed is BCHE; the disease is Lewy body dementia.